2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
03/27/17Enanta Pharmaceuticals to Present at the H.C. Wainwright 1st Annual NASH Investor Conference
Presentation to be Webcast on April 3 at 4:00 pm ET WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 27, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 1st Annual NASH Investor Conference in New ... 
 Printer Friendly Version
03/14/17Enanta Announces Japanese Ministry of Health, Labour and Welfare Grants Priority Review for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C
Priority review in Japan follows EMA accelerated assessment and U.S. FDA priority review designations If approved, G/P may provide a shorter, eight-week, once-daily, ribavirin-free cure* for the majority of the patients living with hepatitis C in Japan1 Glecaprevir is Enanta’s second protease inhibitor being developed through its collaboration with AbbVie and is one of the two new direct-acting antivir... 
 Printer Friendly Version
02/27/17Enanta Announces CHMP Grants Positive Opinion for an Eight-Week Treatment Option with AbbVie’s VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C
CHMP opinion is a step closer to the approval of an eight-week regimen of VIEKIRAX + EXVIERA for previously untreated genotype 1b (GT1b) chronic hepatitis C virus (HCV) patients with minimal to moderate fibrosis* AbbVie’s EMA label expansion is supported by 98 percent SVR12 rate in patients in the dedicated Phase 3b GARNET study1 GT1b is the most common HCV subtype globally and accounts for app... 
 Printer Friendly Version
02/08/17Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2016
WATERTOWN, Mass.--(BUSINESS WIRE)--ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal first quarter ended December 31, 2016.' Enanta Pharmaceuticals, Inc. (ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal fir... 
 Printer Friendly Version
02/06/17Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
Presentations to be Webcast on Feb. 15 and February 22 WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 6, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at each of the following investor conferences: ... 
 Printer Friendly Version
02/02/17Enanta Announces U.S. FDA Grants Priority Review to AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6)
If approved, G/P may provide an eight-week, once-daily, ribavirin-free cure* for HCV patients new to treatment who have any of the major HCV genotypes, without cirrhosis G/P includes Enanta’s second protease inhibitor, glecaprevir (ABT-493) WATERTOWN, Mass.--(BUSINESS WIRE)--Feb. 2, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating s... 
 Printer Friendly Version
01/24/17Enanta Announces EMA Grants Accelerated Assessment, Validates Marketing Authorization Application for AbbVie’s Investigational HCV Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes (GT1-6) of Chronic Hepatitis C
If approved, G/P may provide a shorter, eight-week, once-daily, ribavirin-free treatment option for the majority of HCV patients without cirrhosis MAA is supported by data from global registrational clinical development program across all major HCV genotypes and in patients with specific treatment challenges If approved, AbbVie's G/P regimen could become available for marketing in the European Union (E... 
 Printer Friendly Version
01/23/17Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2016
WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 23, 2017-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal first quarter ended December 31, 2016 after the U.S. markets close on February 8, 2017. Enanta management will host a conference call at 4:30 p... 
 Printer Friendly Version
01/09/17Enanta Announces High SVR12 Rates Achieved in Genotype 1 Chronic HCV Infected Japanese Patients with Eight Weeks of Treatment with AbbVie’s Investigational, Pan-Genotypic, Ribavirin-free Regimen of Glecaprevir/Pibrentasvir (G/P)
In the CERTAIN-1 study, 99 percent (n=105/106) of genotype 1 (GT1) chronic hepatitis C virus (HCV)-infected Japanese patients without cirrhosis achieved SVR12 with 8 weeks of G/P treatment Japan has one of the highest rates of hepatitis C infection in the industrialized world affecting approximately 1 million people, 60 to 70 percent of those are GT11,2,3 G/P includes Enanta’s second protease inhibitor... 
 Printer Friendly Version
01/06/17Enanta Pharmaceuticals Announces Highlights of Business Overview and Update on its Research and Development Programs to be Presented at the 35th Annual J.P. Morgan Healthcare Conference
Enanta to provide updates in all major therapeutic focus areas: NASH/PBC, RSV, HBV, HCV New in vivo data to be presented demonstrating EDP-305 improved pre-established liver injury and hepatic fibrosis in an MCD-induced model of steatohepatitis in mice1 A potent non-fusion inhibitor, EDP-938, selected as a development candidate for RSV, and new in vivo efficacy data to be presented2 WATERTOWN... 
 Printer Friendly Version
01/04/17FDA Grants Fast Track Designation to Enanta’s FXR Agonist Candidate, EDP-305, for the treatment of NASH with Liver Fibrosis
WATERTOWN, Mass.--(BUSINESS WIRE)--Jan. 4, 2017-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Enanta’s drug candidate EDP-305, an FXR agonist, Fast Track designation for the treatment of patients with non-alcoholic steatohepatitis (NASH) wi... 
 Printer Friendly Version
“Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ.”

Email Alerts

Sign up to receive email alerts whenever Enanta Pharmaceuticals Inc posts new information to the site.

Just enter your email address and click Submit.
 

For Media Relations,
please contact:

Kari Watson
MacDougall Biomedical Communications
Phone: (781) 235-3060
Email: kwatson@macbiocom.com

 ;